meRfi®-GM
PIK3CA Mutations
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Patients with PIK3CA mutations and/or PTEN aberrations treated with PI3K/Akt/mTOR inhibitors had a higher clinical response rate (18%) compared with wild-type (WT) PIK3CA patients (6%).
However, initial clinical efforts targeting PIK3CA mutations yielded mixed results because of the lack of isoform specificity of inhibitors and poor therapeutic index.
Copanlisib had mean IC50 values of 19 nM against cell lines with PIK3CA-activa…